New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 18, 2012
19:11 EDTMNOVMedicNova extends MN-166 patent position in Europe
MediciNova announced that it has received Notices of Allowance from the European Patent Office, EPO, for two pending patent applications. One covers the use of ibudilast, MN-166, in drug addiction and the other provides for ibudilast use to enhance opioid analgesia in acute pain settings. MN-166 is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, drug addiction, and pain.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
08:12 EDTMNOVMediciNova announces FDA approval of second Phase 2 protocol for MN-001 in NASH
MediciNova announced that FDA has approved a second protocol for a clinical trial evaluating MN-001 for a NASH indication. This study targets NASH patients with hypertriglyceridemia to evaluate the ability of MN-001 to improve cardiovascular risk by assessing cholesterol-efflux capacity and serum triglyceride levels as well as reduction of percent fat in the liver, as assessed by MRI.
July 21, 2015
08:08 EDTMNOVMediciNova announces update on development plans for MN-001 in IPF
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use